Therefore, inhibiting MISP via nucleic acid therapeutics such as low-molecular-weight inhibitors, antisense nucleotides, and siRNA could be effective in CRC development and progression through two pathways: OIP5, which may regulate critical cellular processes involved in CRC progression such as cell proliferation, survival, and immune evasion, and the JAK2-STAT3 axis, which promotes cancer-promoting activities such as inflammation, proliferation, and anti-apoptotic signaling (Figure 11). The gene discussed is STAT3; the disease is cancer.